Glaxo Group Limited

Ian Richard Catchpole

Alan Peter Lewis

Jonathan Henry Ellis

Volker Germaschewski

Susannah Karen Ford

Peter Ernest Soden

Claire Ashman

Trevor Anthony Kenneth Wattam

Michael Steward

Stephen Anthony Burbidge

Umesh Kumar

Karen Louise Philpott

Gerald Wayne Gough

Zoe Hughes-Thomas

Philippe Marc Louis Alard

Pamela Joan Thomas

The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.

Antigen binding constructs

Antigen binding proteins that bind &#x3b2;-amyloid peptide, in particular human &#x3b2;-amyloid peptide; methods of treating diseases or disorders characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, including age related macular degeneration and glaucoma type diseases and &#x3b2;-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.

Humanized anti-beta-amyloid antibodies

The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and &#x3b2;-amyloid dependent cataract formation, with antigen binding proteins that bind &#x3b2;-amyloid peptide and in particular human &#x3b2;-amyloid peptide.

Antigen binding proteins

Growing community of inventors

Stevenage, United Kingdom

Ian Richard Catchpole